Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
SNY logo SNY
Upturn stock ratingUpturn stock rating
SNY logo

Sanofi ADR (SNY)

Upturn stock ratingUpturn stock rating
$49.94
Last Close (24-hour delay)
Profit since last BUY-2.75%
upturn advisory
Consider higher Upturn Star rating
BUY since 5 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: SNY (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

11 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $62.17

1 Year Target Price $62.17

Analysts Price Target For last 52 week
$62.17 Target price
52w Low $43.86
Current$49.94
52w High $57.57

Analysis of Past Performance

Type Stock
Historic Profit -1.73%
Avg. Invested days 34
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 122.15B USD
Price to earnings Ratio 16.65
1Y Target Price 62.17
Price to earnings Ratio 16.65
1Y Target Price 62.17
Volume (30-day avg) 11
Beta 0.41
52 Weeks Range 43.86 - 57.57
Updated Date 08/29/2025
52 Weeks Range 43.86 - 57.57
Updated Date 08/29/2025
Dividends yield (FY) 7.82%
Basic EPS (TTM) 3

Analyzing Revenue: Products, Geography and Growth

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin 19.95%
Operating Margin (TTM) 18%

Management Effectiveness

Return on Assets (TTM) 4.61%
Return on Equity (TTM) 9%

Valuation

Trailing PE 16.65
Forward PE 11.15
Enterprise Value 130835607051
Price to Sales(TTM) 2.67
Enterprise Value 130835607051
Price to Sales(TTM) 2.67
Enterprise Value to Revenue 2.46
Enterprise Value to EBITDA 8.92
Shares Outstanding 2438960128
Shares Floating 1096299469
Shares Outstanding 2438960128
Shares Floating 1096299469
Percent Insiders -
Percent Institutions 10.28

ai summary icon Upturn AI SWOT

Sanofi ADR

stock logo

Company Overview

overview logo History and Background

Sanofi ADR represents the American Depositary Receipt of Sanofi, a French multinational pharmaceutical company headquartered in Paris. Founded in 1994 through the merger of Synthu00e9labo and Sanofi, it has grown through acquisitions and R&D to become a leading global healthcare player.

business area logo Core Business Areas

  • Pharmaceuticals: Focuses on prescription drugs for various therapeutic areas, including cardiovascular, diabetes, oncology, and immunology.
  • Vaccines (Sanofi Pasteur): Develops and manufactures vaccines for infectious diseases like influenza, polio, and meningitis.
  • Consumer Healthcare: Offers over-the-counter medications and health products for pain relief, allergy, digestive health, and personal care.

leadership logo Leadership and Structure

Sanofi is led by a CEO and a management board, with a supervisory board overseeing strategic direction. The company operates globally with regional and functional divisions.

Top Products and Market Share

overview logo Key Offerings

  • Dupixent: A monoclonal antibody used to treat atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Generated significant revenue growth. Competitors: Amgen's Tezspire, Regeneron's Rinvoq.
  • Influenza Vaccines: Sanofi Pasteur is a major player in the influenza vaccine market. Competitors: GSK, CSL Seqirus.
  • Lantus: A long-acting insulin analog used to treat diabetes (biosimilars now available). Competitors: Novo Nordisk, Eli Lilly.

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry is characterized by high R&D costs, regulatory scrutiny, and patent protection. Growth is driven by aging populations, increasing healthcare spending, and innovative therapies.

Positioning

Sanofi is a diversified pharmaceutical company with a strong presence in vaccines and specialty care. Its competitive advantages include a broad product portfolio, global reach, and R&D capabilities.

Total Addressable Market (TAM)

The global pharmaceuticals market is estimated to be worth over $1.4 trillion. Sanofi targets specific segments of this market including immunology, vaccines and specialty care. Sanofi is well positioned within its target markets.

Upturn SWOT Analysis

Strengths

  • Diversified product portfolio
  • Global presence and distribution network
  • Strong R&D capabilities
  • Leading position in vaccines
  • Established brand reputation

Weaknesses

  • Patent expirations
  • Dependence on key products
  • Exposure to regulatory risks
  • Competition from biosimilars
  • High R&D costs

Opportunities

  • Developing innovative therapies
  • Expanding into emerging markets
  • Acquiring promising assets
  • Partnering with biotech companies
  • Increasing demand for vaccines

Threats

  • Generic competition
  • Pricing pressures
  • Regulatory changes
  • Economic downturns
  • Clinical trial failures

Competitors and Market Share

competitor logo Key Competitors

  • JNJ
  • MRK
  • PFE
  • NVS
  • LLY

Competitive Landscape

Sanofi competes with other large pharmaceutical companies on innovation, pricing, and market access. Its strengths include a diversified portfolio and global presence, while its weaknesses include patent expirations and regulatory risks.

Major Acquisitions

Translate Bio

  • Year: 2021
  • Acquisition Price (USD millions): 3200
  • Strategic Rationale: To expand Sanofi's mRNA technology capabilities and accelerate vaccine and therapeutic development.

Growth Trajectory and Initiatives

Historical Growth: Sanofi's growth has been driven by acquisitions, new product launches, and geographic expansion. However, patent expirations have created headwinds.

Future Projections: Analysts expect Sanofi to achieve moderate revenue growth in the coming years, driven by new product launches and emerging markets. Earnings growth is expected to be higher due to cost-cutting initiatives.

Recent Initiatives: Sanofi has been focusing on developing innovative therapies in areas like immunology and oncology. It has also been streamlining its operations and investing in digital technologies.

Summary

Sanofi is a large, diversified pharmaceutical company with a strong global presence. The company is well-positioned in vaccines and specialty care, but faces challenges from patent expirations and competition. Key growth drivers include new product launches and expansion into emerging markets. Sanofi needs to continue investing in R&D and managing its cost structure to maintain its competitive advantage.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Filings (SEC)
  • Financial News Outlets (e.g., Reuters, Bloomberg)
  • Analyst Reports
  • Company Website

Disclaimers:

The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is approximate and may vary depending on the source.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Sanofi ADR

Exchange NASDAQ
Headquaters -
IPO Launch date 2002-07-01
CEO & Director Mr. Paul Hudson
Sector Healthcare
Industry Drug Manufacturers - General
Full time employees 82878
Full time employees 82878

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, yellow fever, and rabies vaccines. In addition, the company has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Innate Pharma SA for a natural killer cell engager program targeting B7-H3; and Blackstone Life Sciences to develop pivotal studies and clinical development program. Further, it has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop novel targeted protein degradation therapies; Denali Therapeutics Inc. to treat a range of systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for the discovery and development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab, as well as an strategic alliance with the Department of Health " Abu Dhabi for the development of global vaccines. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incor